{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:47:51Z","timestamp":1791301671932,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>Recent studies have identified recurrent isocitrate dehydrogenase 2 (<jats:italic toggle=\"yes\">IDH2<\/jats:italic>) mutations in a subset of sinonasal undifferentiated carcinomas (SNUCs); however, the true frequency of <jats:italic toggle=\"yes\">IDH<\/jats:italic> mutations in SNUC is unknown. We evaluated the utility of mutation-specific IDH1\/2 immunohistochemistry (IHC) in a large multi-institutional cohort of SNUC and morphologic mimics. IHC using a multispecific antibody for IDH1\/2 (R132\/R172) mutant protein was performed on 193 sinonasal tumors including: 53 SNUCs, 8 poorly differentiated carcinomas (PDCARs) and 132 histologic mimics. Mutant IDH1\/2 IHC was positive in 26\/53 SNUCs (49%; 20 strongly positive and 6 weak) and 3\/8 PDCARs (37.5%; 2 strong; 1 weak) but was absent in all other tumor types (0\/132). Targeted next-generation sequencing (NGS) on a subset of SNUC\/PDCAR (6 strong and 3 weak positive for IDH1\/2 IHC; 7 negative) showed frequent <jats:italic toggle=\"yes\">IDH2<\/jats:italic> R172X mutations (10\/16) and a single <jats:italic toggle=\"yes\">IDH1<\/jats:italic> R132C mutation. All 6 cases with strong positive mutant IDH1\/2 staining and NGS had <jats:italic toggle=\"yes\">IDH2<\/jats:italic> R172S\/G mutations. The 3 IHC-weak cases all had <jats:italic toggle=\"yes\">IDH2<\/jats:italic> R172T mutations. Among the 7 tested cases that were negative for mutant IDH1\/2 IHC, NGS detected 1 case each with <jats:italic toggle=\"yes\">IDH2<\/jats:italic> R172T and <jats:italic toggle=\"yes\">IDH1<\/jats:italic> R132C mutation. <jats:italic toggle=\"yes\">IDH-<\/jats:italic>mutant carcinomas also had frequent mutations in <jats:italic toggle=\"yes\">TP53<\/jats:italic> (55%) and activating mutations in <jats:italic toggle=\"yes\">KIT<\/jats:italic> (45%) or the PI3K pathway (36%). Mutation-specific IDH1\/2 IHC identifies <jats:italic toggle=\"yes\">IDH<\/jats:italic> mutations in SNUC, however, it lacks sensitivity for the full range of <jats:italic toggle=\"yes\">IDH<\/jats:italic> mutations. These findings suggest that <jats:italic toggle=\"yes\">IDH<\/jats:italic>-mutant sinonasal carcinoma may represent a distinct pathobiological entity with therapeutic implications that can be identified by a combined approach of multispecific IDH1\/2 IHC and sequencing.<\/jats:p>","DOI":"10.1097\/pas.0000000000001064","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T22:47:46Z","timestamp":1524264466000},"page":"1067-1075","source":"Crossref","is-referenced-by-count":62,"title":["Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas"],"prefix":"10.1097","volume":"42","author":[{"given":"Jeffrey K.","family":"Mito","sequence":"first","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Bishop","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Sadow","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Stelow","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Faquin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey E.","family":"Mills","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey F.","family":"Krane","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"French","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.M.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette M.","family":"Sholl","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Center for Advanced Molecular Diagnostics, Brigham and Women\u2019s Hospital and Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie Y.","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2014.97","article-title":"Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances","volume":"11","author":"Llorente","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00000478-198611000-00004","article-title":"Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma","volume":"10","author":"Frierson","year":"1986","journal-title":"Am J Surg Pathol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0194599812440932","article-title":"Meta-analysis of treatment outcomes for sinonasal undifferentiated carcinoma","volume":"147","author":"Reiersen","year":"2012","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R4-20230922","first-page":"94","article-title":"Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States","volume":"76","author":"Chambers","year":"2015","journal-title":"J Neurol Surg B Skull Base"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.anndiagpath.2014.01.003","article-title":"Role of p40 and cytokeratin 5\/6 in the differential diagnosis of sinonasal undifferentiated carcinoma","volume":"18","author":"Singh","year":"2014","journal-title":"Ann Diagn Pathol"},{"key":"R7-20230922","first-page":"304","article-title":"BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/PAS.0b013e31815a3900","article-title":"NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract","volume":"32","author":"Stelow","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/PAS.0b013e3182698673","article-title":"Human papillomavirus-related carcinomas of the sinonasal tract","volume":"37","author":"Bishop","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1097\/PAS.0000000000000944","article-title":"HPV-related multiphenotypic sinonasal carcinoma: an expanded series of 49 cases of the tumor formerly known as HPV-related carcinoma with adenoid cystic carcinoma-like features","volume":"41","author":"Bishop","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/PAS.0000000000000797","article-title":"SMARCB1 (INI-1)-deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity","volume":"41","author":"Agaimy","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/PAS.0000000000000285","article-title":"SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract","volume":"38","author":"Bishop","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12105-017-0783-4","article-title":"SMARCA4-deficient Sinonasal Carcinoma","volume":"11","author":"Agaimy","year":"2017","journal-title":"Head Neck Pathol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/modpathol.2016.239","article-title":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma","volume":"30","author":"Jo","year":"2017","journal-title":"Mod Pathol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/path.4915","article-title":"Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas","volume":"242","author":"Dogan","year":"2017","journal-title":"J Pathol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1038\/s41598-017-14065-w","article-title":"A brain penetrant mutant IDH1 inhibitor provides in vivo survival benefit","volume":"7","author":"Kopinja","year":"2017","journal-title":"Sci Rep"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/annonc\/mdx079","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","volume":"28","author":"Guo","year":"2017","journal-title":"Ann Oncol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1620\/tjem.230.103","article-title":"Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations","volume":"230","author":"Kato Kaneko","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cam4.149","article-title":"Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1","volume":"2","author":"Liu","year":"2013","journal-title":"Cancer Med"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1002\/cncr.30781","article-title":"Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy","volume":"123","author":"Ali","year":"2017","journal-title":"Cancer"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cncr.31131","article-title":"Genomic profiles of nasopharyngeal carcinoma: the importance of histological subtyping and Epstein-Barr virus in situ assays","volume":"124","author":"Lui","year":"2018","journal-title":"Cancer"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"14121","DOI":"10.1038\/ncomms14121","article-title":"Exome and genome sequencing of nasopharynx cancer identifies NF-kappaB pathway activating mutations","volume":"8","author":"Li","year":"2017","journal-title":"Nat Commun"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/ng.3006","article-title":"The genomic landscape of nasopharyngeal carcinoma","volume":"46","author":"Lin","year":"2014","journal-title":"Nat Genet"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"11283","DOI":"10.1073\/pnas.1607606113","article-title":"Whole-exome sequencing identifies multiple loss-of-function mutations of NF-kappaB pathway regulators in nasopharyngeal carcinoma","volume":"113","author":"Zheng","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nrc3410","article-title":"Medulloblastomics: the end of the beginning","volume":"12","author":"Northcott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1073\/pnas.1013751108","article-title":"The chromatin-remodeling enzyme BRG1 modulates vascular Wnt signaling at two levels","volume":"108","author":"Griffin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-13-1333","article-title":"Molecular pathways: isocitrate dehydrogenase mutations in cancer","volume":"22","author":"Clark","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J Pathol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann Oncol"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.18632\/oncotarget.1408","article-title":"5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft","volume":"4","author":"Borodovsky","year":"2013","journal-title":"Oncotarget"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.18632\/oncotarget.1412","article-title":"Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine","volume":"4","author":"Turcan","year":"2013","journal-title":"Oncotarget"},{"key":"R40-20230922","first-page":"9","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201808000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:28:33Z","timestamp":1695421713000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201808000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001064","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}